A novel serum biomarker quintet reveals added prognostic value when combined with standard clinical parameters in prostate cancer patients by predicting biochemical recurrence and adverse pathology

The objective was to determine the prognostic utility of a new biomarker combination in prostate cancer (PCa) patients undergoing Radical Prostatectomy (RP). Serum samples and clinical data of 557 men who underwent RP for PCa with pathological stage (pT) <3 at Martini Clinic (Hamburg, Germany) we...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Alcibiade Athanasiou, Pierre Tennstedt, Anja Wittig, Ramy Huber, Oliver Straub, Ralph Schiess, Thomas Steuber
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/56f17c082e9f44e1923d13fd0a9636b0
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:56f17c082e9f44e1923d13fd0a9636b0
record_format	dspace
spelling	oai:doaj.org-article:56f17c082e9f44e1923d13fd0a9636b02021-11-25T06:11:04ZA novel serum biomarker quintet reveals added prognostic value when combined with standard clinical parameters in prostate cancer patients by predicting biochemical recurrence and adverse pathology1932-6203https://doaj.org/article/56f17c082e9f44e1923d13fd0a9636b02021-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8589165/?tool=EBIhttps://doaj.org/toc/1932-6203The objective was to determine the prognostic utility of a new biomarker combination in prostate cancer (PCa) patients undergoing Radical Prostatectomy (RP). Serum samples and clinical data of 557 men who underwent RP for PCa with pathological stage (pT) <3 at Martini Clinic (Hamburg, Germany) were used for analysis. Clinical Grade Group and clinical stage was determined using biopsy samples while tumor marker concentrations were measured in serum using immunoassays. The prognostic utility of the proposed marker combination was assessed using Cox proportional hazard regression and Kaplan-Meier analysis. The performance was compared to the Cancer of the Prostate Risk Assessment (CAPRA) score in the overall cohort and in a low-risk patient subset. A multivariable model comprising fibronectin 1, galectin-3-binding protein, lumican, matrix metalloprotease 9, thrombospondin-1 and PSA together with clinical Grade Group (GG) and clinical stage (cT) was created. The proposed model was a significant predictor of biochemical recurrence (BCR) (HR 1.29 per 5 units score, 95%CI 1.20–1.38, p<0.001). The Kaplan-Meier analysis showed that the proposed model had a better prediction for low-risk disease after RP compared to CAPRA (respectively 5.0% vs. 9.1% chance of BCR). In a pre-defined low risk population subset, the risk of BCR using the proposed model was below 5.2% and thus lower when compared to CAPRA = 0–2 (9%), GG<2 (7%) and NCCN = low-risk (6%) subsets. Additionally, the proposed model could significantly (p<0.001) discriminate patients with adverse pathology (AP) events at RP from those without. In conclusion, the proposed model is superior to CAPRA for the prediction of BCR after RP in the overall cohort as well as a in a pre-defined low risk patient population subset. It is also significantly associated with AP at RP.Alcibiade AthanasiouPierre TennstedtAnja WittigRamy HuberOliver StraubRalph SchiessThomas SteuberPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 16, Iss 11 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Alcibiade Athanasiou Pierre Tennstedt Anja Wittig Ramy Huber Oliver Straub Ralph Schiess Thomas Steuber A novel serum biomarker quintet reveals added prognostic value when combined with standard clinical parameters in prostate cancer patients by predicting biochemical recurrence and adverse pathology
description	The objective was to determine the prognostic utility of a new biomarker combination in prostate cancer (PCa) patients undergoing Radical Prostatectomy (RP). Serum samples and clinical data of 557 men who underwent RP for PCa with pathological stage (pT) <3 at Martini Clinic (Hamburg, Germany) were used for analysis. Clinical Grade Group and clinical stage was determined using biopsy samples while tumor marker concentrations were measured in serum using immunoassays. The prognostic utility of the proposed marker combination was assessed using Cox proportional hazard regression and Kaplan-Meier analysis. The performance was compared to the Cancer of the Prostate Risk Assessment (CAPRA) score in the overall cohort and in a low-risk patient subset. A multivariable model comprising fibronectin 1, galectin-3-binding protein, lumican, matrix metalloprotease 9, thrombospondin-1 and PSA together with clinical Grade Group (GG) and clinical stage (cT) was created. The proposed model was a significant predictor of biochemical recurrence (BCR) (HR 1.29 per 5 units score, 95%CI 1.20–1.38, p<0.001). The Kaplan-Meier analysis showed that the proposed model had a better prediction for low-risk disease after RP compared to CAPRA (respectively 5.0% vs. 9.1% chance of BCR). In a pre-defined low risk population subset, the risk of BCR using the proposed model was below 5.2% and thus lower when compared to CAPRA = 0–2 (9%), GG<2 (7%) and NCCN = low-risk (6%) subsets. Additionally, the proposed model could significantly (p<0.001) discriminate patients with adverse pathology (AP) events at RP from those without. In conclusion, the proposed model is superior to CAPRA for the prediction of BCR after RP in the overall cohort as well as a in a pre-defined low risk patient population subset. It is also significantly associated with AP at RP.
format	article
author	Alcibiade Athanasiou Pierre Tennstedt Anja Wittig Ramy Huber Oliver Straub Ralph Schiess Thomas Steuber
author_facet	Alcibiade Athanasiou Pierre Tennstedt Anja Wittig Ramy Huber Oliver Straub Ralph Schiess Thomas Steuber
author_sort	Alcibiade Athanasiou
title	A novel serum biomarker quintet reveals added prognostic value when combined with standard clinical parameters in prostate cancer patients by predicting biochemical recurrence and adverse pathology
title_short	A novel serum biomarker quintet reveals added prognostic value when combined with standard clinical parameters in prostate cancer patients by predicting biochemical recurrence and adverse pathology
title_full	A novel serum biomarker quintet reveals added prognostic value when combined with standard clinical parameters in prostate cancer patients by predicting biochemical recurrence and adverse pathology
title_fullStr	A novel serum biomarker quintet reveals added prognostic value when combined with standard clinical parameters in prostate cancer patients by predicting biochemical recurrence and adverse pathology
title_full_unstemmed	A novel serum biomarker quintet reveals added prognostic value when combined with standard clinical parameters in prostate cancer patients by predicting biochemical recurrence and adverse pathology
title_sort	novel serum biomarker quintet reveals added prognostic value when combined with standard clinical parameters in prostate cancer patients by predicting biochemical recurrence and adverse pathology
publisher	Public Library of Science (PLoS)
publishDate	2021
url	https://doaj.org/article/56f17c082e9f44e1923d13fd0a9636b0
work_keys_str_mv	AT alcibiadeathanasiou anovelserumbiomarkerquintetrevealsaddedprognosticvaluewhencombinedwithstandardclinicalparametersinprostatecancerpatientsbypredictingbiochemicalrecurrenceandadversepathology AT pierretennstedt anovelserumbiomarkerquintetrevealsaddedprognosticvaluewhencombinedwithstandardclinicalparametersinprostatecancerpatientsbypredictingbiochemicalrecurrenceandadversepathology AT anjawittig anovelserumbiomarkerquintetrevealsaddedprognosticvaluewhencombinedwithstandardclinicalparametersinprostatecancerpatientsbypredictingbiochemicalrecurrenceandadversepathology AT ramyhuber anovelserumbiomarkerquintetrevealsaddedprognosticvaluewhencombinedwithstandardclinicalparametersinprostatecancerpatientsbypredictingbiochemicalrecurrenceandadversepathology AT oliverstraub anovelserumbiomarkerquintetrevealsaddedprognosticvaluewhencombinedwithstandardclinicalparametersinprostatecancerpatientsbypredictingbiochemicalrecurrenceandadversepathology AT ralphschiess anovelserumbiomarkerquintetrevealsaddedprognosticvaluewhencombinedwithstandardclinicalparametersinprostatecancerpatientsbypredictingbiochemicalrecurrenceandadversepathology AT thomassteuber anovelserumbiomarkerquintetrevealsaddedprognosticvaluewhencombinedwithstandardclinicalparametersinprostatecancerpatientsbypredictingbiochemicalrecurrenceandadversepathology AT alcibiadeathanasiou novelserumbiomarkerquintetrevealsaddedprognosticvaluewhencombinedwithstandardclinicalparametersinprostatecancerpatientsbypredictingbiochemicalrecurrenceandadversepathology AT pierretennstedt novelserumbiomarkerquintetrevealsaddedprognosticvaluewhencombinedwithstandardclinicalparametersinprostatecancerpatientsbypredictingbiochemicalrecurrenceandadversepathology AT anjawittig novelserumbiomarkerquintetrevealsaddedprognosticvaluewhencombinedwithstandardclinicalparametersinprostatecancerpatientsbypredictingbiochemicalrecurrenceandadversepathology AT ramyhuber novelserumbiomarkerquintetrevealsaddedprognosticvaluewhencombinedwithstandardclinicalparametersinprostatecancerpatientsbypredictingbiochemicalrecurrenceandadversepathology AT oliverstraub novelserumbiomarkerquintetrevealsaddedprognosticvaluewhencombinedwithstandardclinicalparametersinprostatecancerpatientsbypredictingbiochemicalrecurrenceandadversepathology AT ralphschiess novelserumbiomarkerquintetrevealsaddedprognosticvaluewhencombinedwithstandardclinicalparametersinprostatecancerpatientsbypredictingbiochemicalrecurrenceandadversepathology AT thomassteuber novelserumbiomarkerquintetrevealsaddedprognosticvaluewhencombinedwithstandardclinicalparametersinprostatecancerpatientsbypredictingbiochemicalrecurrenceandadversepathology
_version_	1718414041052872704

A novel serum biomarker quintet reveals added prognostic value when combined with standard clinical parameters in prostate cancer patients by predicting biochemical recurrence and adverse pathology

Ejemplares similares